Abstract
Ovarian cancer continues to present a significant health challenge with little progress being made over the past two decades in reducing the incidence and mortality. More recently, novel therapeutics have emerged as a potential way of improving outcomes for women with advanced ovarian cancer who harbor mutations in genes involved in homologous recombination (HR), most notably BRCA1 and BRCA2. In the United States, Olaparib, a PARP inhibitor, has been recently approved for ovarian cancer patients treated with three or more lines of prior chemotherapy who harbor germline mutations in BRCA1 or BRCA2. As a caveat to Olaparib’s FDA approval, BRACAnalysis CDx® was approved as a companion diagnostic test for women with ovarian cancer to determine their BRCA1/2 mutation status and eligibility for treatment. This review article will provide essential background information on hereditary breast and ovarian cancer (HBOC), describe the therapeutic mechanism of PARP inhibitors, and will chronicle the current and emerging homologous recombination deficiency (HRD) assays and their associated patents.
Keywords: Homologous recombination deficiency, gene mutations, synthetic lethality, genetic testing, BRCA1, BRCA2, olaparib, rucaparib, hereditary breast and ovarian cancer.
Graphical Abstract
Recent Patents on Biotechnology
Title:Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Volume: 9 Issue: 2
Author(s): Christopher J. LaFargue, Krishnansu S. Tewari and Gareth K. Forde
Affiliation:
Keywords: Homologous recombination deficiency, gene mutations, synthetic lethality, genetic testing, BRCA1, BRCA2, olaparib, rucaparib, hereditary breast and ovarian cancer.
Abstract: Ovarian cancer continues to present a significant health challenge with little progress being made over the past two decades in reducing the incidence and mortality. More recently, novel therapeutics have emerged as a potential way of improving outcomes for women with advanced ovarian cancer who harbor mutations in genes involved in homologous recombination (HR), most notably BRCA1 and BRCA2. In the United States, Olaparib, a PARP inhibitor, has been recently approved for ovarian cancer patients treated with three or more lines of prior chemotherapy who harbor germline mutations in BRCA1 or BRCA2. As a caveat to Olaparib’s FDA approval, BRACAnalysis CDx® was approved as a companion diagnostic test for women with ovarian cancer to determine their BRCA1/2 mutation status and eligibility for treatment. This review article will provide essential background information on hereditary breast and ovarian cancer (HBOC), describe the therapeutic mechanism of PARP inhibitors, and will chronicle the current and emerging homologous recombination deficiency (HRD) assays and their associated patents.
Export Options
About this article
Cite this article as:
LaFargue J. Christopher, Tewari S. Krishnansu and Forde K. Gareth, Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer, Recent Patents on Biotechnology 2015; 9 (2) . https://dx.doi.org/10.2174/187220830902160308184054
DOI https://dx.doi.org/10.2174/187220830902160308184054 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Approaches and Oxygen Radical Measurement as Biomarker Candidates of Off-Season Predictor of Pollinosis: A Pilot Study
Current Pharmacogenomics and Personalized Medicine The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Fertility Drugs and Ovarian Cancer
Current Cancer Drug Targets Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry The Mitochondrial Thioredoxin is Required for Liver Development in Zebrafish
Current Molecular Medicine 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Cancer Drug Targets Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Plant Natural Products in Anticancer Drug Discovery
Current Organic Chemistry Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Gonadotropin-Releasing Hormone Receptor System: Modulatory Role in Aging and Neurodegeneration
CNS & Neurological Disorders - Drug Targets E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Potential Role for High and Low Molecular Weight Tissue Transglutaminases in Transforming Mammalian Cell Properties
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Natural Products and their Analogues as Efficient Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design